Medpace Holdings (MEDP)
Nasdaq Market Closed
Medpace Holdings, Inc. is a contract research organization that supports drug, biologic, and medical device developers through the clinical development process. The company focuses on full-service outsourced research, helping customers design, manage, and execute clinical trials that are typically required before a therapy can be submitted for regulatory approval. Its client base is weighted toward small and mid-sized biotechnology, pharmaceutical, and device companies, many of which rely on external partners for operational scale and therapeutic expertise.
Medpace offers services across areas such as clinical trial management, regulatory affairs, medical monitoring, data management, biostatistics, pharmacovigilance, and clinical operations. It also provides specialized support through central laboratory, bioanalytical laboratory, imaging, and other ancillary capabilities. This integrated model is designed to reduce the need for customers to coordinate multiple vendors during complex studies.
The company is headquartered in Cincinnati, Ohio, and operates across major clinical research markets in North America, Europe, Asia-Pacific, Latin America, Africa, and Australia. Its global footprint allows it to recruit patients, manage investigator sites, and conduct trials across different healthcare systems and regulatory environments.
Founded more than three decades ago, Medpace has built a reputation around a therapeutically focused and physician-led operating approach. In the broader healthcare market, it competes with other CROs that benefit from the long-term trend of drug developers outsourcing clinical development work. For investors, Medpace represents exposure to clinical research spending rather than direct ownership of a specific drug pipeline.
Last updated
- Market Cap
- 12.73B
- P/E
- 27.64
- P/FCF
- 17.9
- P/S
- 4.75
- Enterprise Value
- 12.07B
- Sector
- Industrials
- Industry
- Commercial Physical and Biological Research
- Address
- 5375 MEDPACE WAY, CINCINNATI, OH, 45227
Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
MEDPACE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
MEDPACE DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Medpace Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VERI
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Medpace Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
ROSEN, LEADING INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGC
Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
LU DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Lufax Holding Ltd Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action First Filed by the Firm - LU
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
DEADLINE ALERT for PINS, NUAI, GOSS, MEDP: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Defendants Allegedly Violated Securities Disclosure Laws: Levi & Korsinsky
ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analysts Allegedly Misled by Guidance: Levi & Korsinsky
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 12.73B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 12.07B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 27.64
- P/B
P/B ratio compares a company's share price to its book value per share.
- 21.27
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 4.75
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 20.43
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 4.51
- EPS
- 16.12
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 17.9
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 17.22
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 711M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 76.95%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 21.62%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 0.85
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.85
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.49
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 426.3K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 445.59
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 706.6M | 708.45M | 659.9M | 603.31M | 558.57M |
| Gross profit | 196.33M | 205.32M | 196.94M | 180.01M | 178.35M |
| Operating income | 141.5M | 153.27M | 141.81M | 126.34M | 113.52M |
| EBITDA | 148.41M | 160.4M | 148.86M | 133.35M | 120.45M |
| Net income | 123.87M | 135.13M | 111.14M | 90.26M | 114.6M |
| Basic EPS | 4.35 | 4.76 | 3.95 | 3.16 | 3.77 |
| Diluted EPS | 4.28 | 4.64 | 3.86 | 3.1 | 3.67 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 2.13B | 1.98B | 1.75B | 1.57B | 1.9B |
| Total liabilities | 1.53B | 1.52B | 1.46B | 1.4B | 1.3B |
| Total equity | 598.31M | 459.07M | 293.64M | 172.35M | 593.61M |
| Cash & equivalents | 652.68M | 497.05M | 285.35M | 46.33M | 441.44M |
| Current assets | 1.14B | 989.62M | 737.29M | 520.81M | 821.44M |
| Current liabilities | 1.35B | 1.34B | 1.28B | 1.22B | 1.12B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 151.79M | 192.65M | 246.21M | 148.53M | 125.84M |
| Investing cash flow | -6.75M | -4.47M | -10.66M | -6.02M | -9.99M |
| Financing cash flow | 12.67M | 22.73M | 3.41M | -540.56M | -345.97M |
| Change in cash | 155.63M | 211.7M | 239.02M | -395.11M | -228M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 144 — Medpace Holdings, Inc. | View Filing | |
| form 4 | Form 4 — EWALD STEPHEN P | View Filing | |
| form 4 | Form 4 — EWALD STEPHEN P | View Filing | |
| form 4 | Form 4 — EWALD STEPHEN P | View Filing | |
| edgar index | 8-K — Medpace Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| form 4 | Form 4 — DAVENPORT FRED B JR | View Filing | |
| form 4 | Form 4 — DAVENPORT FRED B JR | View Filing | |
| form 4 | Form 4 — DAVENPORT FRED B JR | View Filing | |
| form 4 | Form 4 — Kraft Robert O. | View Filing | |
| form 4 | Form 4 — Kraft Robert O. | View Filing | |
| form 4 | Form 4 — Carley Brian T | View Filing | |
| form 4 | Form 4 — Carley Brian T | View Filing | |
| form 4 | Form 4 — McCarthy Cornelius P. III | View Filing | |
| form 4 | Form 4 — McCarthy Cornelius P. III | View Filing | |
| form 4 | Form 4 — Gwadry-Sridhar Femida H. | View Filing | |
| form 4 | Form 4 — Zander Dani S. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| form 4 | Form 4 — Troendle August J. | View Filing | |
| form 4 | Form 4 — Troendle August J. | View Filing | |
| form 4 | Form 4 — Troendle August J. | View Filing | |
| form 4 | Form 4 — Troendle August J. | View Filing | |
| form 4 | Form 4 — EWALD STEPHEN P | View Filing | |
| form 4 | Form 4 — EWALD STEPHEN P | View Filing | |
| form 4 | Form 4 — EWALD STEPHEN P | View Filing | |
| form 4 | Form 4 — EWALD STEPHEN P | View Filing | |
| form 4 | Form 4 — BURWIG SUSAN E | View Filing | |
| form 4 | Form 4 — BURWIG SUSAN E | View Filing | |
| form 4 | Form 4 — BURWIG SUSAN E | View Filing | |
| form 4 | Form 4 — Brady Kevin M. | View Filing | |
| form 4 | Form 4 — Brady Kevin M. | View Filing | |
| form 4 | Form 4 — Brady Kevin M. | View Filing | |
| form 4 | Form 4 — Brady Kevin M. | View Filing | |
| edgar index | 10-Q — Medpace Holdings, Inc. | View Filing | |
| edgar index | 8-K — Medpace Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | ARS — Medpace Holdings, Inc. | View Filing | |
| edgar index | DEF 14A — Medpace Holdings, Inc. | View Filing | |
| edgar index | DEFA14A — Medpace Holdings, Inc. | View Filing | |
| form 4 | Form 4 — Kraft Robert O. | View Filing | |
| form 4 | Form 4 — Kraft Robert O. | View Filing | |
| form 4 | Form 4 — Carley Brian T | View Filing | |
| form 4 | Form 4 — Carley Brian T | View Filing | |
| form 4 | Form 4 — McCarthy Cornelius P. III | View Filing | |
| form 4 | Form 4 — McCarthy Cornelius P. III | View Filing | |
| edgar index | SCHEDULE 13G/A — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| form 4 | Form 4 — BURWIG SUSAN E | View Filing | |
| form 4 | Form 4 — BURWIG SUSAN E | View Filing | |
| edgar index | 144 — Medpace Holdings, Inc. | View Filing | |
| form 4 | Form 4 — GEIGER JESSE J | View Filing | |
| form 4 | Form 4 — GEIGER JESSE J | View Filing | |
| form 4 | Form 4 — GEIGER JESSE J | View Filing | |
| edgar index | PRE 14A — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| edgar index | 4 — Medpace Holdings, Inc. | View Filing | |
| form 4 | Form 4 — EWALD STEPHEN P | View Filing | |
| form 4 | Form 4 — EWALD STEPHEN P | View Filing | |
| form 4 | Form 4 — BURWIG SUSAN E | View Filing | |
| form 4 | Form 4 — BURWIG SUSAN E | View Filing |